Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 10,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares in the company, valued at approximately $81,702,353.72. This represents a 1.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, February 27th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $144.79, for a total value of $1,447,900.00.
• On Thursday, February 5th, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $128.84 on Thursday. The stock’s 50 day moving average price is $140.90 and its 200 day moving average price is $132.36. The firm has a market capitalization of $159.92 billion, a PE ratio of 19.03, a price-to-earnings-growth ratio of 1.69 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. Gilead Sciences, Inc. has a one year low of $95.29 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. Gilead Sciences’s payout ratio is currently 48.45%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley raised its price target to $175 and maintained an “overweight” rating, implying roughly 36% upside from recent levels—a bullish analyst signal that can support the stock. Morgan Stanley Adjusts Gilead Sciences Price Target to $175
• Positive Sentiment: The U.S. FDA accepted Gilead’s NDA for a once-daily bictegravir + lenacapavir HIV regimen and granted priority review with a PDUFA action date in August—this shortens and de-risks a path to U.S. commercialization if approved. U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment
• Positive Sentiment: Gilead completed its acquisition of Arcellx for about $7.8B, adding the anito-cel cell therapy to its oncology portfolio—this expands growth optionality in cell therapy ahead of potential commercial launches. Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
• Positive Sentiment: Technical analysts noted Gilead is retesting a long-term breakout (an 11-year cup base), arguing upside of ~35% is possible if the breakout holds—this can attract momentum and technical buying. Gilead Sciences Crosses Critical Breakout Level
• Neutral Sentiment: Several market pieces referenced broader biotech/healthcare dynamics (Amgen earnings context; IBB ETF discussion) that may influence sector flows into or out of Gilead but are not Gilead-specific catalysts. Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities—this raises governance and IP-policy scrutiny that could create disclosure/headline risk and pressure valuation around future exclusivity-derived revenue. AHF’s Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Analyst Ratings Changes

A number of brokerages have commented on GILD. Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a report on Tuesday, April 7th. Barclays initiated coverage on Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price for the company. TD Cowen lifted their target price on Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $157.35.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. CFS Investment Advisory Services LLC increased its position in shares of Gilead Sciences by 5.2% in the 1st quarter. CFS Investment Advisory Services LLC now owns 12,205 shares of the biopharmaceutical company’s stock worth $1,680,000 after purchasing an additional 601 shares during the last quarter. Montag A & Associates Inc. lifted its position in shares of Gilead Sciences by 9.5% during the first quarter. Montag A & Associates Inc. now owns 3,471 shares of the biopharmaceutical company’s stock worth $484,000 after purchasing an additional 301 shares during the last quarter. Eads & Heald Wealth Management bought a new position in shares of Gilead Sciences during the first quarter worth about $854,000. WealthPLAN Partners LLC acquired a new position in Gilead Sciences in the first quarter worth about $258,000. Finally, Resonant Capital Advisors LLC increased its holdings in Gilead Sciences by 7.7% in the first quarter. Resonant Capital Advisors LLC now owns 30,046 shares of the biopharmaceutical company’s stock valued at $4,188,000 after buying an additional 2,146 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.